Cryoablation treatment for advanced bone and soft tissue tumors
Safety and Efficacy of Cryoablation in the Treatment of Advanced Bone and Soft Tissue Tumors: a Single-center Retrospective Study
This study looks at whether cryoablation treatment can safely help people with advanced bone and soft tissue tumors that can't be removed by surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Sex | All |
| Sponsor | Henan Cancer Hospital Government |
| Locations | 1 site (Zhengzhou, Henan) |
| Trial ID | NCT05615545 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with metastatic or surgically unresectable bone and soft tissue sarcomas who have undergone cryoablation of selected tumor lesions. It is a single-center, open, retrospective study that collects clinical data from eligible patients treated between December 2016 and February 2022. The study evaluates the efficacy and safety of cryoablation by analyzing basic patient data and treatment methods.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with metastatic or locally unresectable bone and soft tissue sarcomas who have undergone cryoablation.
Not a fit: Patients with sarcomas that are resectable or those who have not undergone cryoablation may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a new treatment option for patients with advanced sarcomas that are difficult to manage surgically.
How similar studies have performed: While this study is observational and retrospective, similar approaches using cryoablation for tumor treatment have shown promise in other studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: No age restriction, male or female. The pathological diagnosis was a subtype of bone and soft tissue sarcoma. The clinical stage was determined to be metastatic or locally unresectable bone and soft tissue sarcoma. At least one cryoablation of tumor lesions was performed in our hospital. Target lesions can be evaluated according to the efficacy evaluation criteria for solid tumors (RECIST; Version 1.1) Measure diameter changes. Follow-up data were complete. Exclusion Criteria: Not applicable.
Where this trial is running
Zhengzhou, Henan
- Department of Bone and Soft Tissue ,Henan Cancer Hospital — Zhengzhou, Henan, China (Recruiting)
Study contacts
- Study coordinator: Wang Jiaqiang, Dr
- Email: wjqwtj@126.com
- Phone: 13592413731
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.